Parallax Volatility Advisers’s Cytokinetics CYTK Stock Holding History

Parallax Volatility Advisers’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,000	Closed	-$127K	–	1549
2025 Q4	$127K	Hold	2,000	–	–	﹤0.01%	1424
2025 Q3	$110K	Hold	2,000	–	–	﹤0.01%	1416
2025 Q2	$66.1K	Hold	2,000	–	–	﹤0.01%	1418
2025 Q1	$80.4K	Sell	2,000 -5,600	-74%	-$257K	﹤0.01%	1376
2024 Q4	$358K	Buy	7,600 +300	+4%	+$15.6K	﹤0.01%	1566
2024 Q3	$385K	Sell	7,300 -2,700	-27%	-$150K	﹤0.01%	1571
2024 Q2	$542K	Buy	10,000 +6,700	+203%	+$404K	﹤0.01%	1421
2024 Q1	$231K	Sell	3,300 -4,300	-57%	-$333K	﹤0.01%	1529
2023 Q4	$635K	Buy	+7,600	New	+$275K	﹤0.01%	1539
2023 Q1	–	Sell	-56,500	Closed	-$2.59M	–	2805
2022 Q4	$2.59M	Sell	56,500 -5,000	-8%	-$215K	﹤0.01%	1304
2022 Q3	$2.98M	Buy	+61,500	New	+$2.96M	﹤0.01%	1230
2020 Q4	–	Sell	-3,900	Closed	-$84K	–	2730
2020 Q3	$84K	Buy	+3,900	New	+$91.2K	﹤0.01%	2757

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Parallax Volatility Advisers's CYTK Position: Q1 2026 in Review

Parallax Volatility Advisers sold out of Cytokinetics (CYTK) in Q1 2026, closing a stake of 3,039 shares — an estimated $193K sold.

Parallax Volatility Advisers first reported a position in CYTK in Q4 2017 and held it in 12 quarters. The position peaked at $2.03M in Q3 2024. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

Parallax Volatility Advisers reported no remaining Cytokinetics position as of Q1 2026 after selling out during the quarter.
Parallax Volatility Advisers sold 3,039 Cytokinetics shares in Q1 2026, an estimated $193K.
Parallax Volatility Advisers first reported a position in Cytokinetics in Q4 2017 and held it in 12 quarters.
Parallax Volatility Advisers's Cytokinetics position peaked at $2.03M in Q3 2024.
439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Parallax Volatility Advisers's 13F filing for Q1 2026, filed 15 May 2026.